(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Germany's Merz under fire in Brazil for his comments on Amazon host city of COP30 - 2Eleven arrested over mass shooting in South Africa tavern
- 3Sweet Taste? Candy Fulfills You
- 4Senegal president signs tough new anti-LGBT law doubling jail terms
- 5MEPs urge Commission leaders to stop Russia from returning to the Venice Biennale
- Grasping the Elements of Medical caretaker Pay rates: Factors That Shape Your Pay
- Overlooked infertility care should be part of national health services, says WHO
- What's The Friendliest City In The United Kingdom?
- They grew up with 'almond moms.' Now, they dread going home for the holidays.
- Exhaustive Experiences into Prudent Senior Living in the UK
- Louisiana seeks California doctor’s extradition, testing the limits of shield laws
- You finally got a doctor's appointment. Here's how to get the most out of it
- Windows to the Previous: An Excursion Through the World's Notable Engineering
- A 3-limbed Kemp's ridley sea turtle is now being tracked at sea by satellite
